The use of colistin in critically ill children in a pediatric intensive care unit

Pediatric Infectious Disease Journal

Volumn 33, Issue 1, 2014, Pages

  Karbuz, Adem ^a   Özdemir, Halil ^a   Yaman, Ayhan ^a   Kocabaş, Bilge Aldemir ^a   Ödek, Çaǧlar ^a   Güriz, Haluk ^a   Aysev, Ahmet Derya ^a   Çiftçi, Ergin ^a   Kendirli, Tanil ^a   Ateş, Can ^a   Ince, Erdal ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; NEOMYCIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; BACTEREMIA; BLOODSTREAM INFECTION; BRAIN VENTRICLE PERITONEUM SHUNT; CHILD; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; ENTEROBACTER CLOACAE; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PERITONITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SCHOOL CHILD; SERRATIA MARCESCENS; SHUNT INFECTION; STENOTROPHOMONAS MALTOPHILIA; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COLISTIN; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891500002     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000117     Document Type: Review

References (29)

1. Li J, Nation RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589-601
2. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005;49:3136-3146
3. Yahav D, Farbman L, Leibovici L, et al. Colistin: New lessons on an old antibiotic. Clin Microbiol Infect. 2012;18:18-29
4. Cheng CY, Sheng WH, Wang JT, et al. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gramnegative bacterial infections. Int J Antimicrob Agents. 2010;35:297-300
5. Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents. 2005;26:504-507
6. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857-868
7. Rosanova M, Epelbaum C, Noman A, et al. Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res. 2009;30:612-615
8. Paksu MS, Paksu S, Karadag A, et al. Old agent, new experience: Colistin use in the paediatric Intensive Care Unit-a multicentre study. Int J Antimicrob Agents. 2012;40:140-144
9. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents. 2009;33:503.e1-503.e13
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Seventeenth Information Supplement. Wayne, PA: CLSI; 2007 [Document M100-S17
11. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-332
12. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-281
13. Iosifidis E, Antachopoulos C, Ioannidou M, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867-874
14. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-199
15. Goverman J, Weber JM, Keaney TJ, et al. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. J Burn Care Res. 2007;28:421-426
16. Furtado GH, d'Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30:315-319
17. Ouderkirk JP, Nord JA, Turett GS, et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gramnegative bacteria. Antimicrob Agents Chemother. 2003;47:2659-2662
18. Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci. 2011;26:325-331
19. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154-e160
20. Michalopoulos AS, Falagas ME. Colistin: Recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011;1:30
21. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: Prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019-1027
22. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gramnegative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-121
23. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-1726
24. Olesen S, Madsen PO. Intravenous administration of sodium colistimethate in urinary tract infections. Curr Ther Res Clin Exp. 1967;9:283-287
25. Baines RD Jr, Rifkind D. Intravenous administration of sodium colistimethate. JAMA. 1964;190:278-281
26. Falagas ME, Sideri G, Vouloumanou EK, et al. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J. 2009;28:123-127
27. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724-1728
28. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistinassociated nephrotoxicity. J Infect. 2011;62:187-190
29. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27